Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IBRX NASDAQ:LKFT NASDAQ:PRAX NASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$7.36$7.55$1.95▼$12.43$7.71B0.0312.29 million shs14.33 million shsLKFTLakefront Biotherapeutics American Depositary Shares$28.30$28.15$26.42▼$37.78$1.86B0.26179,517 shs159,488 shsPRAXPraxis Precision Medicines$282.31$315.29$37.19▼$366.52$7.87B2.71523,564 shs684,321 shsSYRESpyre Therapeutics$88.34$73.21$14.00▼$90.99$7.67B3.051.07 million shs2.42 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio0.00%+3.66%-8.57%-13.11%+159.15%LKFTLakefront Biotherapeutics American Depositary Shares0.00%-2.08%+3.28%-11.59%+0.28%PRAXPraxis Precision Medicines0.00%+5.90%-15.88%-5.36%+556.99%SYRESpyre Therapeutics0.00%+9.35%+22.83%+114.16%+485.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBRXImmunityBio$7.36$7.55$1.95▼$12.43$7.71B0.0312.29 million shs14.33 million shsLKFTLakefront Biotherapeutics American Depositary Shares$28.30$28.15$26.42▼$37.78$1.86B0.26179,517 shs159,488 shsPRAXPraxis Precision Medicines$282.31$315.29$37.19▼$366.52$7.87B2.71523,564 shs684,321 shsSYRESpyre Therapeutics$88.34$73.21$14.00▼$90.99$7.67B3.051.07 million shs2.42 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBRXImmunityBio0.00%+3.66%-8.57%-13.11%+159.15%LKFTLakefront Biotherapeutics American Depositary Shares0.00%-2.08%+3.28%-11.59%+0.28%PRAXPraxis Precision Medicines0.00%+5.90%-15.88%-5.36%+556.99%SYRESpyre Therapeutics0.00%+9.35%+22.83%+114.16%+485.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBRXImmunityBio 2.71Moderate Buy$14.2092.93% UpsideLKFTLakefront Biotherapeutics American Depositary Shares 2.13Hold$36.5028.98% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$566.21100.56% UpsideSYRESpyre Therapeutics 3.00Buy$94.176.60% UpsideCurrent Analyst Ratings BreakdownLatest LKFT, PRAX, IBRX, and SYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2026PRAXPraxis Precision Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$449.006/17/2026PRAXPraxis Precision Medicines Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy6/16/2026SYRESpyre Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$100.006/15/2026SYRESpyre Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$98.00 ➝ $112.006/8/2026LKFTLakefront Biotherapeutics American Depositary Shares Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/4/2026SYRESpyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/4/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$102.00 ➝ $115.006/2/2026PRAXPraxis Precision Medicines TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026PRAXPraxis Precision Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$715.00 ➝ $616.006/2/2026PRAXPraxis Precision Medicines OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$750.00 ➝ $650.006/2/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.00 ➝ $810.00(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBRXImmunityBio$140.98M54.68N/AN/A($0.51) per share-14.43LKFTLakefront Biotherapeutics American Depositary Shares$1.26B1.48$0.73 per share38.98$47.57 per share0.59PRAXPraxis Precision Medicines$8.55M920.56N/AN/A$34.85 per share8.10SYRESpyre Therapeutics$890K8,619.60N/AN/A$7.21 per share12.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBRXImmunityBio-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%8/4/2026 (Estimated)LKFTLakefront Biotherapeutics American Depositary Shares$363.05M-$1.41N/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)SYRESpyre Therapeutics-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)Latest LKFT, PRAX, IBRX, and SYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026IBRXImmunityBio-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/6/2026Q1 2026LKFTLakefront Biotherapeutics American Depositary Shares-$1.27$0.25+$1.52$0.25$11.26 million$8.75 million5/5/2026Q1 2026SYRESpyre Therapeutics-$0.66-$0.74-$0.08-$0.74$70.87 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIBRXImmunityBioN/AN/AN/AN/AN/ALKFTLakefront Biotherapeutics American Depositary SharesN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBRXImmunityBioN/A6.676.66LKFTLakefront Biotherapeutics American Depositary SharesN/A30.4830.30PRAXPraxis Precision MedicinesN/A15.8815.88SYRESpyre TherapeuticsN/A8.978.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBRXImmunityBio8.58%LKFTLakefront Biotherapeutics American Depositary Shares32.46%PRAXPraxis Precision Medicines67.84%SYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipIBRXImmunityBio66.10%LKFTLakefront Biotherapeutics American Depositary Shares2.91%PRAXPraxis Precision Medicines3.00%SYRESpyre Therapeutics15.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBRXImmunityBio5901.05 billion355.05 millionOptionableLKFTLakefront Biotherapeutics American Depositary Shares1,31065.90 million63.98 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.04 millionOptionableSYRESpyre Therapeutics7386.84 million73.22 millionOptionableLKFT, PRAX, IBRX, and SYRE HeadlinesRecent News About These CompaniesSpyre Therapeutics Inc SYREJune 18 at 8:23 PM | morningstar.comMAnalysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and Tyra Bioscience (TYRA)June 18 at 8:23 PM | theglobeandmail.comSpyre Therapeutics Extends Long-Acting Antibody Program in IBD With New Long-Term StudyJune 18 at 1:10 PM | tipranks.comPerceptive Advisors LLC Buys 1,839,780 Shares of Spyre Therapeutics, Inc. $SYREJune 18 at 7:17 AM | marketbeat.comSpyre Therapeutics, Inc. $SYRE Stock Position Boosted by Commodore Capital LPJune 18 at 5:08 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Hits New 12-Month High - Should You Buy?June 17 at 4:08 AM | americanbankingnews.comAnalysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Cogstate Ltd (COGZF)June 16, 2026 | theglobeandmail.comSpyre Expands SPY003 Rights Beyond Inflammatory Bowel DiseaseJune 16, 2026 | theglobeandmail.comSpyre says bowel disease drug cuts inflammation in mid-stage trialJune 15, 2026 | reuters.comSpyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsJune 15, 2026 | globenewswire.comHealthcare ETFs: From Broad Exposure to Big BreakthroughsJune 11, 2026 | etftrends.comECapital International Investors Purchases 1,100,000 Shares of Spyre Therapeutics, Inc. $SYREJune 9, 2026 | marketbeat.comSpyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comSpyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside PotentialJune 5, 2026 | finance.yahoo.comSpyre Therapeutics Announces Grants of Inducement AwardsJune 5, 2026 | globenewswire.comArrowpoint Investment Partners Singapore Pte. Ltd. Buys New Shares in Spyre Therapeutics, Inc. $SYREJune 5, 2026 | marketbeat.comSYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock UpJune 4, 2026 | zacks.comScott Burrows Sells 7,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockJune 4, 2026 | insidertrades.comSpyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpAJune 3, 2026 | globenewswire.comWhy Spyre Therapeutics (SYRE) Is Down 6.1% After Broadening Its SPY003 Paragon License TermsJune 3, 2026 | finance.yahoo.comSeven Grand Managers LLC Buys Shares of 100,000 Spyre Therapeutics, Inc. $SYREMay 28, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLKFT, PRAX, IBRX, and SYRE Company DescriptionsImmunityBio NASDAQ:IBRX$7.36 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$7.33 -0.03 (-0.42%) As of 06/18/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT$28.30 0.00 (0.00%) As of 06/18/2026 04:00 PM EasternGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.Praxis Precision Medicines NASDAQ:PRAX$282.31 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$282.31 0.00 (0.00%) As of 06/18/2026 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Spyre Therapeutics NASDAQ:SYRE$88.34 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$88.38 +0.05 (+0.05%) As of 06/18/2026 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
